Compositions and methods for treatment of bleeding disorders
AssigneeBand Therapeutics, LLC
InventorsJames C. GILBERT, Shuhao ZHU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to treatment of bleeding disorders, in particular, hemophilia A (mild, moderate or severe hemophilia) and von Willebrand disease (VWD), Type 1 or Type 2 or Type 3, using VWF targeting agents such as a PEGylated anti-VWF aptamer, BT200.
Claims35
A method for treating a hereditary bleeding disorder in a subject comprising administering to the subject a therapeutic effective amount of a pharmaceutic composition comprising a VWF targeting agent.
A method for preventing a chronic bleeding condition, and/or spontaneous bleeding in a subject comprising administering to the subject a therapeutic effective amount of a pharmaceutic composition comprising a VWF targeting agent.
A method for blocking VWF clearance in the blood comprising providing an effective amount of a VWF targeting agent that is a synthetic polynucleotide comprising a PEGylation moiety.
A method for elevating the FVIII levels in the blood of a subject comprising administering to the subject an efficient amount of a composition comprising a VWF targeting agent that is a synthetic polynucleotide comprising a PEGylation moiety.
A method for increasing platelet counts in the blood of a patient comprising administering to the patient an efficient amount of a composition comprising BT200 (SEQ ID No.:
- 6), wherein the patient has a low platelet count (thrombocytopenia).
A method for treating a hereditary bleeding disorder in a patient with a pharmaceutical composition comprising a VWF binding agent, BT200, comprising:
- a) assessing the hereditary bleeding disorder of said patient and the baseline coagulation function in said patient;
- b) determining the optimal dose of BT200 with the assessment of step a) for initial treatment;
- and
- c) providing a weekly dose of BT200 after one-week treatment with the initial dose of BT200 in said patient.
Dependencies are inferred from the claim text.